3-溴-2-氧代樟脑烷-8-磺酸 | 63808-77-5

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 异戊烯醇脂质
• 中文名称: 3-溴-2-氧代樟脑烷-8-磺酸
• 英文名称: (+)-α-bromo-π-camphorsulfonic acid
• 英文别名: (+)-3-bromocamphorsulfonic acid；(+)-α-Brom-ϖ-camphersulfonsaeure；3-Bromo-2-oxobornane-8-sulphonic acid；(3-bromo-1,7-dimethyl-2-oxo-7-bicyclo[2.2.1]heptanyl)methanesulfonic acid
• CAS: 63808-77-5
• 化学式: C₁₀H₁₅BrO₄S
• 分子量: 311.197
• InChiKey: MFEDKMBNKNOUPA-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  79.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  methyl 2-amino-2-(fluoromethyl)-3-(1-tritylimidazol-4-yl)propanoate;oxolane 、 3-溴-2-氧代樟脑烷-8-磺酸 生成 (3-bromo-1,7-dimethyl-2-oxo-7-bicyclo[2.2.1]heptanyl)methanesulfonic acid;methyl (2S)-2-amino-2-(fluoromethyl)-3-(1-tritylimidazol-4-yl)propanoate
  参考文献：
  名称：

  KOLLONITSCH, J.;PERKINS, L. M.;DOLDOURAS, G. A.;MARBURG, S.

  摘要：

  DOI：

文献信息

• [EN] PROCESS FOR THE SYNTHESIS OF STABLE AMORPHOUS IBRUTINIB<br/>[FR] PROCÉDÉ DE SYNTHÈSE D'IBRUTINIB AMORPHE STABLE
  申请人：AZAD PHARMACEUTICAL INGREDIENTS AG

  公开号：WO2017137446A1

  公开（公告）日：2017-08-17

  Disclosed herein is a new route of synthesis and a new stable amorphous form of ibrutinib. Also disclosed are pharmaceutical compositions, oral dosage forms and the use of the amorphous ibrutinib in the treatment of mantle cell lymphoma or chronic lymphocytic leukemia.

  本文披露了一种新的合成途径和一种新的稳定非晶态伊布替尼形式。还披露了制药组合物、口服剂型以及在曼特尔细胞淋巴瘤或慢性淋巴细胞白血病治疗中使用非晶态伊布替尼的方法。
• PROCESSES FOR PREPARING JAK INHIBITORS AND RELATED INTERMEDIATE COMPOUNDS
  申请人：Zhou Jiacheng

  公开号：US20100190981A1

  公开（公告）日：2010-07-29

  The present invention is related to processes for preparing chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines of Formula III, and related synthetic intermediate compounds. The chiral substituted pyrazolyl pyrrolo[2,3-d]pyrimidines are useful as inhibitors of the Janus Kinase family of protein tyrosine kinases (JAKs) for treatment of inflammatory diseases, myeloproliferative disorders, and other diseases.

  本发明涉及制备手性取代吡唑基吡咯并[2,3-d]嘧啶的公式III的过程，以及相关的合成中间体化合物。这些手性取代吡唑基吡咯并[2,3-d]嘧啶可用作抑制Janus激酶家族蛋白酪氨酸激酶（JAKs）的药物，用于治疗炎症性疾病、骨髓增生性疾病和其他疾病。
• [EN] SITAGLIPTIN SYNTHESIS<br/>[FR] SYNTHÈSE DE LA SITAGLIPTINE
  申请人：GENERICS UK LTD

  公开号：WO2010131025A1

  公开（公告）日：2010-11-18

  The present invention relates to novel processes for the preparation of enantiomerically enriched β -amino acid derivatives such as β -amino esters useful for the synthesis of enantiomerically enriched biologically active molecules such as sitagliptin. The key step involves the resolution of the racemate with mandelic acid.

  本发明涉及一种用于制备对映富集的β-氨基酸衍生物的新工艺，例如对合成对映富集的生物活性分子如西格列汀有用的β-氨基酯。关键步骤包括用苯甲酸对消旋体进行拆分。
• Method for producing chiral mercapto amino acids
  申请人：Kotthaus Martina

  公开号：US20070112216A1

  公开（公告）日：2007-05-17

  The invention relates to a method for producing chiral mercapto amino acids of formula (I) wherein R 1 , R 2 and R 3 can represent hydrogen, C 6 -C 12 aryl, C 1 -C 6 -alkyl-C 6 -C 12 -aryl, C 6 -C 12 -aryl-C 1 -C 6 -alkyl, C 1 -C 18 -alkyl or C 2 -C 18 -alkenyl, R 2 and R 3 forming a saturated or unsaturated ring. According to said method, a) an oxo compound of formula (II), wherein X represents a leaving group, is reacted in the presence of ammonia or ammonium hydroxide and a sulfide, optionally under phase transfer catalysis or addition of a solubiliser, with a ketone or an aldehyde of formula (III) wherein R 4 and R 5 can represent a C 1 -C 12 alkyl radical or a C 6 -C 20 aryl radical or one of the two radicals H, or R 4 and R 5 together form a C 4 -C 7 ring, to form the compound of formula (IV), that b) reacts with HCN to form the corresponding nitrile, whereupon c) the crystallised nitrile is converted, by selective hydrolysis by means of a mineral acid, into the corresponding amide of formula (VI), and d) is then converted into the corresponding chiral amide of formula (VI*) by means of an L amidase or a chiral dissociating acid, whereupon by reaction with an acid, the desired chiral mercapto amino acid of formula (I) is obtained, or e) first the reaction with an acid is carried out, and then the conversion into the chiral mercapto amino acid takes place.

  该发明涉及一种生产手性巯基氨基酸的方法，其化学式为(I)，其中R1、R2和R3可以代表氢、C6-C12芳基、C1-C6烷基-C6-C12芳基、C6-C12芳基-C1-C6烷基、C1-C18烷基或C2-C18烯基，R2和R3形成饱和或不饱和环。根据该方法，a）在氨或氢氧化铵存在下，将具有化学式(II)的羰基化合物，其中X代表离去基团，与具有化学式(III)的酮或醛反应，其中R4和R5可以代表C1-C12烷基基团或C6-C20芳基基团或两个基团H中的一个，或者R4和R5一起形成C4-C7环，形成具有化学式(IV)的化合物，然后b）与HCN反应形成相应的腈，随后c）通过矿酸的选择性水解将结晶的腈转化为具有化学式(VI)的相应酰胺，并且d）通过L-酰胺酶或手性分离酸将其转化为具有化学式(VI*)的相应手性酰胺，然后通过与酸的反应得到所需的手性巯基氨基酸，或者e）首先进行与酸的反应，然后进行转化为手性巯基氨基酸。
• SITAGLIPTIN SYNTHESIS
  申请人：Gore Vinayak Govind

  公开号：US20120108598A1

  公开（公告）日：2012-05-03

  The present invention relates to novel processes for the preparation of enantiomerically enriched β-amino acid derivatives such as β-amino esters useful for the synthesis of enantiomerically enriched biologically active molecules such as sitagliptin. The key step involves the resolution of the racemate with mandelic acid.

  本发明涉及一种用于制备对映富集的β-氨基酸衍生物的新工艺，例如用于合成对映富集的生物活性分子如西他列汀的β-氨基酯。关键步骤涉及用苯甲酸解析外消旋体。